Challenges and optimal strategies of CAR T therapy for hematological malignancies

Remarkable improvement relative to traditional approaches in the treatment of hematological malignancies by chimeric antigen receptor (CAR) T-cell therapy has promoted sequential approvals of eight commercial CAR T products within last 5 years. Although CAR T cells’ productization is now rapidly boo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yajing, Xu, Yang, Dang, Xiuyong, Zhu, Zeyu, Qian, Wenbin, Liang, Aibin, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106177/
https://www.ncbi.nlm.nih.gov/pubmed/36848181
http://dx.doi.org/10.1097/CM9.0000000000002476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106177/
https://www.ncbi.nlm.nih.gov/pubmed/36848181
http://dx.doi.org/10.1097/CM9.0000000000002476

Ejemplares similares